سعر كارفالون 25 مجم 20 قرص مغلف 2025

Carfalone 25 mg film-coated tablets (Marcyrl); eplerenone selective mineralocorticoid receptor antagonist.

• Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF ≤40%) after an acute myocardial infarction.Population: Adults post-MI with HFrEFDailyMed / FDA
• Treatment of hypertension in adults, to lower blood pressure (alone or with other antihypertensives).Population: AdultsDailyMed / FDA

• HFrEF post-MI: most common adverse reactions more frequent than placebo were hyperkalemia and increased creatinine. Hypertension studies: adverse reactions uncommon; discontinuations related to headache, dizziness, angina/MI, increased GGT; gynecomastia and abnormal vaginal bleeding reported.International label, same formulation · DailyMed / FDA

• For all patients: serum potassium >5.5 mEq/L at initiation; creatinine clearance ≤30 mL/min; concomitant strong CYP3A inhibitors. For hypertension treatment additionally: type 2 diabetes with microalbuminuria; serum creatinine >2.0 mg/dL (males) or >1.8 mg/dL (females); CrCl <50 mL/min; concomitant potassium supplements or potassium-sparing diuretics.International label, same formulation · DailyMed / FDA

• Hyperkalemia risk is higher with impaired renal function, proteinuria, diabetes, and concomitant ACEIs/ARBs/NSAIDs/moderate CYP3A inhibitors. Monitor potassium and adjust dose.International label, same formulation · DailyMed / FDA

• Strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, etc.)MajorContraindicated: eplerenone is primarily metabolized by CYP3A.DailyMed / FDA
• Moderate CYP3A inhibitors (erythromycin, saquinavir, verapamil, fluconazole)MajorPost-MI HFrEF: do not exceed 25 mg once daily. Hypertension: initiate 25 mg once daily; max 25 mg twice daily.DailyMed / FDA
• ACE inhibitors and/or ARBsMajorIncreased hyperkalemia risk; monitor potassium and renal function closely.DailyMed / FDA

• Available published case reports are insufficient to establish drug-associated risk of major birth defects, miscarriage, or adverse maternal/fetal outcomes. Animal studies at high exposures showed no teratogenicity. Hypertension and heart failure in pregnancy carry maternal/fetal risks requiring specialist management.International label, same formulation · DailyMed / FDA
• No human data on presence in human milk or effects on the breastfed infant; eplerenone was present in milk of lactating rats.International label, same formulation · DailyMed / FDA

• Eplerenone: Blocks aldosterone binding at mineralocorticoid receptors (US Inspra label).